Dendritic Cell Maturation is a Critical Step in Dendritic Cell Vaccine Preparation for Cancer Therapy
DOI:
https://doi.org/10.17140/VROJ-1-105Keywords:
Cancer vaccine, Dendritic cell, Maturation status, Antitumor activity, Tumor microenvironmentAbstract
Background: Dendritic cell (DC) vaccine is a hopeful approach for cancer treatment. In clinical trials, DC vaccines have produced clinical responses in some cancer patients. However, DC vaccines efficacy is not satisfactory in most types of cancer and more efforts must be done to improve their effectiveness in advanced cancers. Understanding the influence of tumor cells and tumor stromal cells on DCs and the antitumor activity of ex vivo generated DCs in the tumor microenvironment can help to augment antitumor efficiency of ex vivo generated DCs. In a fibrosarcoma tumor model, we explored effects of the tumor microenvironment on the antitumor efficacy of ex vivo generated DCs.
Methods: DCs were generated from mouse bone marrow precursor cells in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). DCs were pulsed with tumor antigens and matured in the presence of tumor necrosis factor-alpha (TNF-α), lipopolysaccharide (LPS), or TNF-α plus LPS. Mature or immature DCs were injected subcutaneously before tumor inoculation or were directly injected into the tumor tissue.
Results: Tumor antigen-pulsed DCs matured in the presence of TNF-α plus LPS showed appropriate functionality in vitro, including IL-12 secretion and induction of lymphocyte proliferation. Tumor lysate-loaded DCs matured in the presence of TNF-α did not show appropriate antitumor function in vivo. Injection of antigen-unpulsed mature DCs two days before tumor inoculation resulted in antitumor effects. In contrast, injection of immature DCs directly into the tumor tissue enhanced the tumor growth.
Conclusion: These results suggest that tumor cells, tumor stromal cells, or tumor derived factors can influence DCs to have tumor-promoting function. Appropriate maturation induction in ex vivo generated DCs and manipulating the tumor microenvironment before DC vaccination may improve antitumor activity of DC vaccines in cancer patients.
References
Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concen-trate macromolecules in the major histocompatibility complex class II compartment: Down regulation by cytokines and bac-terial products. J Exp Med. 1995; 182(2): 389-400. Web site. http://jem.rupress.org/content/182/2/389.long. Accessed August 4, 2016
Chow A, Toomre D, Garrett W, Mellman I. Dendritic cell maturation triggers retrograde MHC class II transport from lyso-somes to the plasma membrane. Nature. 2002; 418(6901): 988- 994. doi: 10.1038/nature01006
Banchereau J, Briere F, Caux C, et al. Immunobiology of den-dritic cells. Ann Rev Immunol. 2000; 18: 767-811. doi: 10.1146/ annurev.immunol.18.1.767
Farashi-Bonab S, Khansari N. Dendritic cell vaccine and its application in cancer therapy. Int J Vaccines Vaccin. 2015; 1(1): 2.
Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med. 1996; 183(1): 283-287. Web site. http://jem.rupress.org/content/183/1/283. long. Accessed August 4, 2016
Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine den-dritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 1996; 183(1): 317-322. doi: 10.1084/jem.183.1.317
Gong J, Chen D, Kashiwaba M, Kufe D. Induction of anti-tumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997; 3(5): 558-561. doi: 10.1038/ nm0597-558
Ma W, Smith T, Bogin V, et al. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: A promising strategy for tumor immunotherapy. J Transl Med. 2011; 9: 34. doi: 10.1186/1479- 5876-9-34
Felizardo TC, Wang JC, McGray RA, et al. Differential im-mune responses mediated by adenovirus-and lentivirus-trans-duced DCs in a HER-2/neu overexpressing tumor model. Gene Ther. 2011; 18(10): 986-995. doi: 10.1038/gt.2011.53
Liu Y, Butterfield LH, Fu X, et al. Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepa-tocellular carcinoma growth in vitro and in vivo. Int J Oncol. 2011; 39(1): 245-253. doi: 10.3892/ijo.2011.1004
Yang HG, Hu BL, Xiao L, Wang P. Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma. Cancer Gene Ther. 2011; 18(5): 370- 380. doi: 10.1038/cgt.2011.13
Miyazawa M, Iwahashi M, Ojima T, et al. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elic-it mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro. Cancer Lett. 2011; 305(1): 32-39. doi: 10.1016/j. canlet.2011.02.013
Theiner G, Rössner S, Dalpke A, et al. TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells. Mol Immunol. 2008; 45(1): 244-252.
Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus WJ. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother. 2007; 30(1): 75- 82. doi: 10.1097/01.cji.0000211316.15278.6e
Xu S, Koski GK, Faries M, et al. Rapid high efficiency sen-sitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recogni-tion through an IL-12-dependent mechanism. J Immunol. 2003; 171(5): 2251-2261. doi: 10.4049/jimmunol.171.5.2251
Jonuleit H, Kuhn U, Muller G, et al. Proinflammatory cy-tokines and prostaglandins induce maturation of potent immu-nostimulatory dendritic cells under fetal calf serum-free con-ditions. Eur J Immunol. 1997; 27: 3135-3142. doi: 10.1002/ eji.1830271209
Kim S, Kim HO, Kim HJ, Lee K, Kim HS. Generation of functionally mature dendritic cells from elutriated monocytes using polyinosinic: Polycytidylic acid and soluble CD40 ligand for clinical application. Clin Exp Immunol. 2008; 154(3): 365- 374. doi: 10.1111/j.1365-2249.2008.03757.x
Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cyto-kine-matured DCs in myeloma patients. Blood. 2006; 108(8): 2655-2661. doi: 10.1182/blood-2006-03-011353
Muthuswamy R, Urban J, Lee JJ, et al. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 2008; 68(14): 5972-5978. doi: 10.1158/0008-5472.CAN-07-6818
Farashi-Bonab S, Khansari N. Regulatory T cells in cancer patients and their roles in cancer development/progression. MOJ Immunol. 2014; 1(4): 00024. doi: 10.15406/moji.2014.01.00024
Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. α-Type-1 polarized dendritic cells: A novel immunization tool with opti-mized CTL inducing activity. Cancer Res. 2004; 64(17): 5934- 5937. doi: 10.1158/0008-5472.CAN-04-1261
Trepiakas R, Pedersen AE, Met O, et al. Comparison of al-pha-Type-1 polarizing and standard dendritic cell cytokine cock-tail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine. 2005; 26(23): 2824-2832. doi: 10.1016/j.vaccine.2008.03.054
Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. In-duction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 1999; 59(16): 4035-4041. Web site. http://cancerres.aacrjournals.org/content/59/16/4035. long. Accessed August 4, 2016
Hu J, Yuan X, Belladonna ML, et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 2006; 66(17): 8887- 8896. doi: 10.1158/0008-5472.CAN-05-3448
Triplett TA, Cardenas KT, Lancaster JN, et al. Endoge-nous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation. Proc Natl Acad Sci USA. 2016; 113(8): E1016-E1025. doi: 10.1073/pnas.1520245113
Watkins SK, Zhu Z, Riboldi E, et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest. 2011; 121(4): 1361-1372. doi: 10.1172/JCI44325
Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of im-mature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol. 2003; 200(2): 255-268. doi: 10.1002/path.1344
Ugolini C, Basolo F, Proietti A, et al. Lymphocyte and im-mature dendritic cell infiltrates in differentiated, poorly differ-entiated, and undifferentiated thyroid carcinoma. Thyroid. 2007; 17(5): 389-393. doi: 10.1089/thy.2006.0306
Scarlett UK, Rutkowski MR, Rauwerdink AM, et al. Ovar-ian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med. 2012; 209(3): 495-506. doi: 10.1084/ jem.20111413
Hargadon KM, Ararso YT, Forrest OA, Harte CM. Mela-noma-associated suppression of the dendritic cell lines DC2.4 and JAWSII. Am J Immunol. 2012; 8(4): 179-190. doi: 10.3844/ ajisp.2012.179.190
Hargadon KM, Bishop JD, Brandt JP, et al. Melanoma-de-rived factors alter the maturation and activation of differentiated tissue-resident dendritic cells. Immunol Cell Biol. 2016; 94(1): 24-38. doi: 10.1038/icb.2015.58
Liu Q, Zhang C, Sun A, et al. Tumor-educated CD11bhighI-alow regulatory dendritic cells suppress T cell response through arginase I. J Immunol. 2009; 182(10): 6207-6216. doi: 10.4049/ jimmunol.0803926
Fainaru O, Almog N, Yung CW, et al. Tumor growth and angiogenesis are dependent on the presence of immature den-dritic cells. FASEB J. 2010; 24(5): 1411-1418. doi: 10.1096/ fj.09-147025
Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med. 2004; 10(9): 950-958. doi: 10.1038/nm1097
Fainaru O, Adini A, Benny O, et al. Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis. FASEB J. 2008; 22(2): 522-529. doi: 10.1096/ fj.07-9034com
Sprague L, Muccioli M, Pate M, et al. The interplay between surfaces and soluble factors define the immunologic and an-giogenic properties of myeloid dendritic cells. BMC Immunol. 2011; 12: 35. doi: 10.1186/1471-2172-12-35
Tzeng TC, Chyou S, Tian S, et al. CD11chi dendritic cells regulate the re-establishment of vascular quiescence and stabi-lization after immune stimulation of lymph nodes. J Immunol. 2010; 184(8): 4247-4257. doi: 10.4049/jimmunol.0902914
Gottfried E, Kreutz M, Haffner S, et al. Differentiation of human tumour-associated dendritic cells into endothelial-like cells: An alternative pathway of tumour angiogenesis. Scand J Immunol. 2007; 65(4): 329-335. doi: 10.1111/j.1365- 3083.2007.01903.x
Lu J, Liu K, Zhao J, et al. VEGF-A not Ang2 mediates endo-thelial-like differentiation of immature DCs by ERK1/2 signal-ing in the microenvironment of human colon adenocarcinoma. Int J Oncol. 2011; 38(6): 1579-1588. doi: 10.3892/ijo.2011.989
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.